Phibro Animal Health Appoints Daniel Bendheim as CEO, Grants Performance-Based RSUs with Aggressive Stock Price Targets
Summary
Phibro Animal Health has appointed Daniel Bendheim as its new CEO, effective July 1, 2026, and granted him 300,000 performance-based restricted stock units tied to ambitious stock price targets of $70-$100 by 2031.
Key Events
-
New CEO Appointed
Daniel Bendheim has been appointed Chief Executive Officer and President, effective July 1, 2026.
-
Significant Performance-Based RSU Grant
Mr. Bendheim received a grant of 300,000 restricted stock units (RSUs), valued at approximately $9.5 million at the current stock price.
-
Aggressive Stock Price Vesting Targets
The RSUs are performance-based and will vest on June 30, 2031, only if the company's 90-day average stock price reaches between $70 and $100, indicating a strong incentive for significant share price appreciation.
-
New Compensation Package
The new CEO's employment agreement includes an annual base salary of $850,000, with target annual bonus and RSU awards each at 50% of his base salary.
Analysis
This filing announces a significant leadership change with the appointment of Daniel Bendheim as the new CEO and President. The accompanying performance-based RSU grant of 300,000 shares is substantial, valued at approximately $9.5 million at current prices. Crucially, these RSUs only vest if the company's stock price reaches between $70 and $100 by June 2031, representing a 121% to 216% increase from the current price. This highly incentivizes the new CEO to drive significant long-term shareholder value.
At the time of this filing, PAHC was trading at $31.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $24.59 to $60.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.